Trial: 201905121

AREN1721 – A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

Phase

II

Principal Investigator

Armstrong, Amy

Disease Site

Kidney

Learn more about this study at: clinicaltrials.gov